SCHEMBL23460936

SCHEMBL23460936

O=C(N[C@H](C(=O)O)C12CC(C(F)(F)F)(C1)C2)c1ccc2ccccc2c1OCc1ccc(SC(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 6/20 0.46
▸ PTPRZ1 P23471 2/20 0.34
▸ KCNK2 O95069 1/20 0.33
▸ KCNK10 P57789 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ LMNA P02545 2/20 0.32
▸ PTPN2 P17706 1/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ PTPN7 P35236 1/20 0.32
▸ KIFC1 Q9BW19 1/20 0.31
▸ NAMPT P43490 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ NR1H4 Q96RI1 2/20 0.31
▸ EPHX2 P34913 1/20 0.31
▸ PPARG P37231 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460939 1.00 CXCR2 (0.46) CXCR2PTPRZ1KCNK2KCNK10ALDH1A1
SCHEMBL25598596 0.91 CXCR2 (0.46) CXCR2PTPRZ1KCNK2KCNK10ALDH1A1
SCHEMBL25602752 0.91 CXCR2 (0.46) CXCR2PTPRZ1KCNK2KCNK10ALDH1A1
SCHEMBL23460922 0.89 CXCR2 (0.56) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL38147003 0.89 CXCR2 (0.56) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL23460921 0.89 CXCR2 (0.56) CXCR2ALDH1A1GAAMAPTKIFC1
SCHEMBL23460088 0.88 CXCR2 (0.46) CXCR2PTPRZ1KCNK2KCNK10ALDH1A1
SCHEMBL25549506 0.88 CXCR2 (0.45) CXCR2ALDH1A1GAAMAPTLMNA
SCHEMBL25548794 0.88 CXCR2 (0.45) CXCR2ALDH1A1GAAMAPTLMNA
SCHEMBL25549217 0.88 CXCR2 (0.45) CXCR2ALDH1A1GAAMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885PTPRZ1 1172/4885KCNK2 1269/4885
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885PTPRZ1 2278/4885KCNK2 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback